Press Releases First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Delayed Nasdaq Other stock markets 12:28:40 2024-04-29 pm EDT			5-day change	1st Jan Change
2.81 ^USD	+2.55%		-3.44%	-33.10%

Mar. 29	First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Sector Update: Health Care Stocks Retreating Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients	Apr. 24	AQ
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase	Apr. 17	AQ
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference	Apr. 15	AQ
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference	Mar. 18	AQ
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline	Mar. 14	AQ
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference	Mar. 05	AQ
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering	Mar. 04	AQ
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024	Feb. 13	AQ
First Wave BioPharma to Present at the DealFlow MicroCap Conference	Jan. 23	AQ
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico	Jan. 17	AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	Jan. 08	AQ
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024	Jan. 04	AQ
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced	Dec. 27	AQ
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program	Dec. 27	AQ
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company	Dec. 18	AQ
First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders	Dec. 14	AQ
First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024”	Dec. 06	AQ
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference	Dec. 05	AQ
Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum	23-10-10	AQ
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference	23-10-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Press Releases

Filters